Details of the Drug Combination

General Information of Drug Combination (ID: DC6UGOJ)

• Drug Combination Name: Crotamiton + Sivelestat
• Indication: Chronic myelogenous leukemia; Status: Investigative [1]
• Component Drugs:
  Crotamiton (DM2TUCU): Small molecular drug
  Sivelestat (DM6BZCV): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: KBM-7
  Zero Interaction Potency (ZIP) Score: 15.52
  Bliss Independence Score: 15.52
  Loewe Additivity Score: 31.39
  LHighest Single Agent (HSA) Score: 31.41

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Crotamiton

Disease Entry	ICD 11	Status	REF
Pruritus	EC90	Approved	[2]

Indication(s) of Sivelestat

Disease Entry	ICD 11	Status	REF
Crohn disease	DD70	Phase 3	[3]
Multiple sclerosis	8A40	Phase 3	[3]
Psoriatic arthritis	FA21	Phase 3	[3]
Pyoderma gangrenosum	EB21	Phase 3	[4]
Rheumatoid arthritis	FA20	Phase 3	[3]
Ulcerative colitis	DD71	Phase 3	[3]
Anterior uveitis	9A96	Application submitted	[5]
Axial spondyloarthritis	FA92.0	Application submitted	[3]

Sivelestat Interacts with 2 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Pancreatic elastase 1 (CELA1)	TT3NKIB	CELA1_HUMAN	Inhibitor	[6]
Neutrophil elastase (NE)	TTPLTSQ	ELNE_HUMAN	Inhibitor	[7]

References

• [1] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] Sivelestat (selective neutrophil elastase inhibitor) improves the mortality rate of sepsis associated with both acute respiratory distress syndrome... Shock. 2010 Jan;33(1):14-8.
• [7] Neutrophil elastase inhibitor (sivelestat) reduces the levels of inflammatory mediators by inhibiting NF-kB. Inflamm Res. 2009 Apr;58(4):198-203.